Vunakizumab in Adults with Spondyloarthritis

Summary

This prospective, single-arm, multicenter study is aimed to explore the efficacy and safety of Vunakizumab in adults with spondyloarthritis. The primary endpoint is the proportion of adults with spondyloarthritis achieving ankylosing spondylitis assessment score (ASAS) 40 at week 16 in the treatment of Vunakizumab.

Timeline

Start

2025-01-10

Primary completion

2026-01-10

Completion

2027-12-31

Drugs

Indications